Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial. [electronic resource]
Producer: 20190619Description: 274-282 p. digitalISSN:- 1873-7560
- Administration, Oral
- Adolescent
- Adrenergic beta-3 Receptor Agonists -- administration & dosage
- Adult
- Aged
- Double-Blind Method
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Humans
- Male
- Middle Aged
- Muscarinic Antagonists -- administration & dosage
- Pyrimidinones -- administration & dosage
- Pyrrolidines -- administration & dosage
- Recovery of Function
- Time Factors
- Tolterodine Tartrate -- administration & dosage
- Treatment Outcome
- Urinary Bladder -- drug effects
- Urinary Bladder, Overactive -- diagnosis
- Urination -- drug effects
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.